Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | Zendy

Meletios Α. Dimopoulos | Zendy; Dominik Dytfeld | Zendy; Sebastian Grosicki | Zendy; Philippe Moreau | Zendy; Naoki Takezako | Zendy; Mitsuo Hori | Zendy; Xavier Leleu | Zendy; Richard LeBlanc | Zendy; Kenshi Suzuki | Zendy; Marc S. Raab | Zendy; Paul G. Richardson | Zendy; Mihaela Popa McKiver | Zendy; Ying-Ming Jou | Zendy; Suresh G. Shelat | Zendy; Michael Robbins | Zendy; Brian T. Rafferty | Zendy; Jesús F. San Miguel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Author(s) -

Meletios Α. Dimopoulos,

Dominik Dytfeld,

Sebastian Grosicki,

Philippe Moreau,

Naoki Takezako,

Mitsuo Hori,

Xavier Leleu,

Richard LeBlanc,

Kenshi Suzuki,

Marc S. Raab,

Paul G. Richardson,

Mihaela Popa McKiver,

Ying-Ming Jou,

Suresh G. Shelat,

Michael Robbins,

Brian T. Rafferty,

Jesús F. San Miguel

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1805762

Subject(s) - pomalidomide , lenalidomide , medicine , multiple myeloma , dexamethasone , hazard ratio , oncology , neutropenia , gastroenterology , chemotherapy , confidence interval

The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research